Australia Health

Echo IQ (ASX:EIQ) executed a binding agreement for a proposed investment of up to $20 million and a partnership with Pro Medicus (ASX:PME).

AFT Pharmaceuticals (ASX:AFP) secured US FDA approval to launch a Phase 3 trial targeting a US$7.41 billion market.

Recce Pharmaceuticals (ASX:RCE) received ethical approval to advance its Australian diabetic foot infection trial to a 200-patient Phase 3 study.

Bupa has executed an agreement to acquire Partnered Health Group to grow its integrated healthcare service footprint across Australia.

Cynata Therapeutics (ASX:CYP) announced its Phase 3 trial of CYP-004 showed no statistically significant differences.

Australian Clinical Labs (ASX:ACL) announced it is contacting approximately 280,000 individuals following a cyber incident at its SunDoctors subsidiary.

BCAL Diagnostics (ASX:BDX) has developed a diagnostic blood test that achieved 91% sensitivity for detecting breast cancer recurrence.

Neurizon Therapeutics (ASX:NUZ) executed an agreement with Elanco Animal Health (NYSE:ELAN) to secure a five-year supply of human-health monepantel.

Island Pharmaceuticals (ASX:ILA) secured US FDA Orphan Drug Designation for Galidesivir.

Racura Oncology (ASX:RAC) has raised $34.3 million to fully fund three upcoming clinical trials.

Dimerix (ASX:DXB) executed a licensing agreement with Everest Medicines to develop and commercialise its clinical-stage drug candidate, DMX-200.

Sigma Healthcare (ASX:SIG) has walked away from preliminary discussions to acquire UK health and beauty retailer Boots.